These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16629780)

  • 21. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.
    Briggs AH; Glick HA; Lozano-Ortega G; Spencer M; Calverley PM; Jones PW; Vestbo J;
    Eur Respir J; 2010 Mar; 35(3):532-9. PubMed ID: 19717476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone.
    Woodcock AA; Bagdonas A; Boonsawat W; Gibbs MR; Bousquet J; Bateman ED;
    Prim Care Respir J; 2007 Jun; 16(3):155-61. PubMed ID: 17551661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation.
    Wan Yau Ming S; Haughney J; Small I; Wolfe S; Hamill J; Gruffydd-Jones K; Daly C; Soriano JB; Gardener E; Skinner D; Stagno d'Alcontres M; Price DB
    Respir Med; 2017 Aug; 129():199-206. PubMed ID: 28732831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation.
    Miller E; FitzGerald JM
    Can J Clin Pharmacol; 2008; 15(2):e165-76. PubMed ID: 18515918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma.
    Gerzeli S; Rognoni C; Quaglini S; Cavallo MC; Cremonesi G; Papi A
    Clin Drug Investig; 2012 Apr; 32(4):253-65. PubMed ID: 22352412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global Initiative for Asthma 2016-derived asthma control with fluticasone propionate and salmeterol: A Gaining Optimal Asthma Control (GOAL) study reanalysis.
    Bateman ED; Busse W; Pedersen SE; Bousquet J; Huang S; Zhou X; Gul N; Hollis S; Gibbs M
    Ann Allergy Asthma Immunol; 2019 Jul; 123(1):57-63.e2. PubMed ID: 31028894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy.
    Price D; Wirén A; Kuna P
    Allergy; 2007 Oct; 62(10):1189-98. PubMed ID: 17845590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study.
    Bousquet J; Barnes N; Gibbs M; Gul N; Tomkins SA; Zhou X; Cho YJ; Park HS; Busse W; Zhong N
    BMC Pulm Med; 2017 Apr; 17(1):75. PubMed ID: 28454528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of addition of salmeterol versus doubling the dose of fluticasone propionate on specific airway resistance in children with asthma.
    Murray CS; Custovic A; Lowe LA; Aldington S; Williams M; Beasley R; Woodcock A
    Allergy Asthma Proc; 2010; 31(5):415-21. PubMed ID: 20929609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
    Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the Gaining Optimal Asthma controL study.
    Pedersen SE; Bateman ED; Bousquet J; Busse WW; Yoxall S; Clark TJ;
    J Allergy Clin Immunol; 2007 Nov; 120(5):1036-42. PubMed ID: 17935765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
    O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
    Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic evaluations.
    Anthonisen NR
    Can Respir J; 2007; 14(5):264-6. PubMed ID: 17874484
    [No Abstract]   [Full Text] [Related]  

  • 38. Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate.
    Rojas RA; Paluga I; Goldfrad CH; Duggan MT; Barnes N
    J Asthma; 2007; 44(6):437-41. PubMed ID: 17654129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy.
    Hagiwara M; Delea TE; Stanford RH; Stempel DA
    Allergy Asthma Proc; 2010; 31(3):203-10. PubMed ID: 20534183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.